All In Biotech

Free tool

FDA Approval Tracker

Original approvals of brand-name drugs and biologics (NDAs and BLAs) and efficacy supplements, which add a new use, population or dose. Approvals by CBER (most vaccines, blood products and cell and gene therapies) are not in Drugs@FDA and so are missing.

Last checked: Nov 20, 2026Latest source record: Nov 9, 2026Drugs@FDA last updated: Nov 18, 2026Methods & limitations

Reset

Matching approvals

31

2023 to 2026

Breakthrough

4

Accelerated

1

Priority review

9

Orphan

8

By year

NDAs and BLAs matching the filters.

  • NDA
  • BLA
View as table
YearNDABLA
202351
202451
202564
202645

31 approvals

Newest first. Hover a badge for what it means.

  • Sunharbo (Asundexian) · Bayer HealthcareNov 9, 2026
    Original approval · NDA 221291NovelPriority reviewApproval letter

    To reduce the risk of stroke in adults following a recent mild-to-moderate non-cardioembolic ischemic stroke or a high-risk transient ischemic attack

  • Onswik (Insulin Efsitora Alfa-Gobe) · Eli Lilly and COSep 23, 2026
    Original approval · BLA 761408NovelApproval letter

    To improve glycemic control in adults with type 2 diabetes mellitus, as an adjunct to diet and exercise

  • Garzulys (Insulin Aspart-Fsan) · Emerge Bioscience Pte. Ltd.Sep 15, 2026
    Original approval · BLA 761497Approval letter
  • Garzulys (Insulin Aspart-Fsan) · Emerge Bioscience Pte. Ltd.Jul 24, 2026
    Original approval · BLA 761497Approval letter
  • Lipfendra (Enlicitide Decanoate) · MsdJul 15, 2026
    Original approval · NDA 220848NovelPriority reviewApproval letter

    To reduce low-density lipoprotein cholesterol

  • Baxfendy (Baxdrostat) · Astrazeneca AbMay 15, 2026
    Original approval · NDA 219878NovelPriority reviewApproval letter

    To treat hypertension in combination with other antihypertensive drugs

  • Langlara (Insulin Glargine-Aldy) · Sunshine Lake Pharma CO LTDApr 29, 2026
    Original approval · BLA 761412Approval letter
  • Foundayo (Orforglipron Calcium) · Eli Lilly and COApr 1, 2026
    Original approval · NDA 220934NovelApproval letter

    To reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition, in combination with a reduced-calorie diet and increased physical activity

  • Awiqli Flextouch (Insulin Icodec) · Novo Nordisk INCMar 26, 2026
    Original approval · BLA 761326NovelOrphanApproval letter
  • Yartemlea (Narsoplimab-Wuug) · Omeros CorpDec 23, 2025
    Original approval · BLA 761152NovelBreakthrough therapyPriority reviewOrphanApproval letter

    To treat hematopoietic stem cell transplant-associated thrombotic microangiopathy

  • Myqorzo (Aficamten) · CytokineticsDec 19, 2025
    Original approval · NDA 219083NovelBreakthrough therapyOrphanApproval letter

    To treat symptomatic obstructive hypertrophic cardiomyopathy

  • Cardamyst (Etripamil) · Milestone Pharms USADec 12, 2025
    Original approval · NDA 218571NovelApproval letter

    To treat episodes of paroxysmal supraventricular tachycardia

  • Lerochol (Lerodalcibep-Liga) · Lib Therapeutics, Inc.Dec 12, 2025
    Original approval · BLA 761427NovelApproval letter

    To reduce low-density lipoprotein cholesterol in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia, as an adjunct to diet and exercise

  • Redemplo (Plozasiran Sodium) · ArrowheadNov 18, 2025
    Original approval · NDA 219947NovelBreakthrough therapyOrphanApproval letter

    To reduce triglycerides in adults with familial chylomicronemia syndrome

  • Wayrilz (Rilzabrutinib) · Genzyme CorpAug 29, 2025
    Original approval · NDA 219685NovelOrphanApproval letter

    To treat persistent or chronic immune thrombocytopenia that has not sufficiently responded to immunoglobulins, anti-D therapy, or corticosteroids

  • Kirsty (Insulin Aspart-Xjhz) · Biocon Biologics INCJul 15, 2025
    Original approval · BLA 761188Approval letter
  • Widaplik (Amlodipine Besylate, Indapamide, Telmisartan) · AzurityJun 5, 2025
    Original approval · NDA 219423Approval letter
  • Eliquis (Apixaban) · BristolApr 17, 2025
    Original approval · NDA 220073Priority reviewApproval letter
  • Merilog (Insulin Aspart-Szjj) · Sanofi-Aventis U.S. LLCFeb 14, 2025
    Original approval · BLA 761325Approval letter
  • Rapiblyk (Landiolol Hydrochloride) · Aop Hlth USNov 22, 2024
    Original approval · NDA 217202NovelApproval letter

    To treat supraventricular tachycardia

  • Attruby (Acoramidis Hydrochloride) · Bridgebio PharmaNov 22, 2024
    Original approval · NDA 216540NovelOrphanApproval letter

    To treat cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis

  • Flyrcado (Flurpiridaz F-18) · Ge HlthcareSep 27, 2024
    Original approval · NDA 215168NovelApproval letter

    A radioactive diagnostic drug to evaluate for myocardial ischemia and infarction

  • Entresto Sprinkle (Sacubitril, Valsartan) · NovartisApr 12, 2024
    Original approval · NDA 218591Approval letter
  • Winrevair (Sotatercept-Csrk) · Merck Sharp DohmeMar 26, 2024
    Original approval · BLA 761363NovelBreakthrough therapyPriority reviewOrphanApproval letter

    To treat pulmonary arterial hypertension

  • Tryvio (Aprocitentan) · IdorsiaMar 19, 2024
    Original approval · NDA 217686NovelApproval letter

    To treat hypertension

  • Zepbound (Tirzepatide) · Eli Lilly and CONov 8, 2023
    Original approval · NDA 217806NovelPriority reviewApproval letter
  • Inpefa (Sotagliflozin) · Lexicon Pharms INCMay 26, 2023
    Original approval · NDA 216203NovelApproval letter

    To treat heart failure

  • Elfabrio (Pegunigalsidase Alfa-Iwxj) · Chiesi Farmaceutici SpaMay 9, 2023
    Original approval · BLA 761161NovelPriority reviewApproval letter

    To treat confirmed Fabry disease

  • Filspari (Sparsentan) · TravereFeb 17, 2023
    Original approval · NDA 216403NovelAccelerated approvalPriority reviewOrphanApproval letter

    To reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk of rapid disease progression

  • Atorvaliq (Atorvastatin Calcium) · Cmp Dev LLCFeb 1, 2023
    Original approval · NDA 213260Approval letter
  • Brenzavvy (Bexagliflozin) · TheracosbioJan 20, 2023
    Original approval · NDA 214373NovelApproval letter

    To improve glycemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.